Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: BioTrack Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series F Financing July 03, 2020
With this new round of funding, CF Pharmtech is more poised than ever to provide respiratory disease treatments for China and global market.